Contact Information
37 Westminster Buildings, Theatre Square,
Nottingham, NG1 6LG
Wells Fargo Initiates Coverage of UDR (UDR) with Overweight Recommendation
On March 29, 2023, Wells Fargo initiated coverage of UDR with a Overweight recommendation. Analyst Price Forecast Suggests 23.08% Upside As of March 28, 2023,
Oppenheimer Initiates Coverage of Trane Technologies (TT) with Perform Recommendation
On March 28, 2023, Oppenheimer initiated coverage of Trane Technologies with a Perform recommendation. Analyst Price Forecast Suggests 8.38% Upside As of March 29, 2023,
Benchmark Initiates Coverage of Repligen (RGEN) with Buy Recommendation
On March 28, 2023, Benchmark initiated coverage of Repligen with a Buy recommendation. Analyst Price Forecast Suggests 23.54% Upside As of March 29, 2023, the
Evercore ISI Group Initiates Coverage of Astria Therapeutics (ATXS) with Outperform Recommendation
On March 28, 2023, Evercore ISI Group initiated coverage of Astria Therapeutics with a Outperform recommendation. Analyst Price Forecast Suggests 114.24% Upside As of March
B of A Securities Initiates Coverage of Foghorn Therapeutics (FHTX) with Buy Recommendation
On March 28, 2023, B of A Securities initiated coverage of Foghorn Therapeutics with a Buy recommendation. Analyst Price Forecast Suggests 254.32% Upside As of
Oppenheimer Initiates Coverage of Lennox International (LII) with Perform Recommendation
On March 28, 2023, Oppenheimer initiated coverage of Lennox International with a Perform recommendation. Analyst Price Forecast Suggests 11.24% Upside As of March 28, 2023,
B. Riley Securities Initiates Coverage of Gritstone Oncology (GRTS) with Buy Recommendation
On March 28, 2023, B. Riley Securities initiated coverage of Gritstone Oncology with a Buy recommendation. Analyst Price Forecast Suggests 259.88% Upside As of March
Morgan Stanley Initiates Coverage of Model N (MODN) with Overweight Recommendation
On March 27, 2023, Morgan Stanley initiated coverage of Model N with a Overweight recommendation. Analyst Price Forecast Suggests 51.64% Upside As of March 26,
RBC Capital Initiates Coverage of Legend Biotech (LEGN) with Outperform Recommendation
On March 24, 2023, RBC Capital initiated coverage of Legend Biotech with a Outperform recommendation. Analyst Price Forecast Suggests 57.86% Upside As of March 25,